All In Biotech

Drug Trial Radar · NCT07463846

A Study to Evaluate ALN-2232 in Participants With Obesity

A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-2232 as Monotherapy and Co-initiated With Tirzepatide in Adult Participants With Obesity

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

156

Planned (sponsor's estimate)

Start

Mar 2, 2026

Primary completion

Apr 28, 2027

Study completion Apr 28, 2028

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Mar 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity

Conditions

  • Obesity

Interventions

  • ALN-2232Drug

    ALN-2232 will be administered subcutaneously (SC)

  • PlaceboDrug

    Placebo will be administered SC

  • TirzepatideDrug

    Tirzepatide will be administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Frequency of Adverse Events (AEs)Time frame: Up to 12 months
  2. Part B: Percent Change from Baseline in Body WeightTime frame: Baseline up to Month 6
  3. Part C: Percent Change from Baseline in Body WeightTime frame: Baseline up to Month 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Mount Royal, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.